Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Many systemic cancer chemotherapies comprise a combination of drugs, yet all clinically
used antibody–drug conjugates (ADCs) contain a single-drug payload. These combination …

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …

Synthetic biology aims to design or assemble existing bioparts or bio-components for useful
bioproperties. During the past decades, progresses have been made to build delicate …

Over 500 natural and synthetic amino acids have been genetically encoded in the last two
decades. Incorporating these noncanonical amino acids into proteins enables many …

Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …

Highlights•Naturally occurring peptides are important resources in order to develop
pharmaceutical lead compounds.•Natural peptides are often limited by poor stability or …

Antibody‐based cancer therapy, one of the most significant therapeutic strategies, has
achieved considerable success and progress over the past decades. Nevertheless …